Steven D Stellman1, Mirjana V Djordjevic. 1. Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, New York, USA. sds91@columbia.edu
Abstract
OBJECTIVE: This Agent paper (II of V on monitoring the tobacco use epidemic) summarizes the findings and recommendations of the Agent (product) Working Group of the November, 2002, National Tobacco Monitoring, Research and Evaluation Workshop. METHODS: The Agent Working Group evaluated the need to develop new surveillance systems for quantifying ingredients and emissions of tobacco and tobacco smoke and to improve methods to assess uptake and metabolism of these constituents taking into account variability in human smoking behavior. RESULTS: The toxic properties of numerous tobacco and tobacco smoke constituents are well known, yet systematic monitoring of tobacco products has historically been limited to tar, nicotine, and CO in mainstream cigarette smoke using a machine-smoking protocol that does not reflect human smoking behavior. Toxicity of smokeless tobacco products has not been regularly monitored. Tobacco products are constantly changing and untested products are introduced into the marketplace with great frequency, including potential reduced-exposure products (PREPs). The public health impact of new or modified tobacco products is unknown. CONCLUSIONS: Systematic surveillance is recommended for mainstream smoke constituents such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines (TSNA), total and free-base nicotine, volatile organic compounds, aromatic amines, and metals; and design attributes including tobacco blend, additives, and filter ventilation. Research on smoking topography is recommended to help define machine-smoking protocols for monitoring emissions reflective of human smoking behavior. Recommendations are made for marketplace product sampling and for population monitoring of smoking topography, emissions of toxic constituents, biomarkers of exposure and, eventually, risk of tobacco-related diseases.
OBJECTIVE: This Agent paper (II of V on monitoring the tobacco use epidemic) summarizes the findings and recommendations of the Agent (product) Working Group of the November, 2002, National Tobacco Monitoring, Research and Evaluation Workshop. METHODS: The Agent Working Group evaluated the need to develop new surveillance systems for quantifying ingredients and emissions of tobacco and tobacco smoke and to improve methods to assess uptake and metabolism of these constituents taking into account variability in human smoking behavior. RESULTS: The toxic properties of numerous tobacco and tobacco smoke constituents are well known, yet systematic monitoring of tobacco products has historically been limited to tar, nicotine, and CO in mainstream cigarette smoke using a machine-smoking protocol that does not reflect human smoking behavior. Toxicity of smokeless tobacco products has not been regularly monitored. Tobacco products are constantly changing and untested products are introduced into the marketplace with great frequency, including potential reduced-exposure products (PREPs). The public health impact of new or modified tobacco products is unknown. CONCLUSIONS: Systematic surveillance is recommended for mainstream smoke constituents such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines (TSNA), total and free-base nicotine, volatile organic compounds, aromatic amines, and metals; and design attributes including tobacco blend, additives, and filter ventilation. Research on smoking topography is recommended to help define machine-smoking protocols for monitoring emissions reflective of human smoking behavior. Recommendations are made for marketplace product sampling and for population monitoring of smoking topography, emissions of toxic constituents, biomarkers of exposure and, eventually, risk of tobacco-related diseases.
Authors: Richard J O'Connor; Gary A Giovino; Lynn T Kozlowski; Saul Shiffman; Andrew Hyland; John T Bernert; Ralph S Caraballo; K Michael Cummings Journal: Am J Epidemiol Date: 2006-08-03 Impact factor: 4.897
Authors: Gary A Giovino; Lois Biener; Anne M Hartman; Stephen E Marcus; Michael W Schooley; Terry F Pechacek; Donna Vallone Journal: Prev Med Date: 2008-09-09 Impact factor: 4.018
Authors: David Hammond; Geoffrey T Fong; K Michael Cummings; Richard J O'Connor; Gary A Giovino; Ann McNeill Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-08 Impact factor: 4.254
Authors: David Hammond; Friedrich Wiebel; Lynn T Kozlowski; Ron Borland; K Michael Cummings; Richard J O'Connor; Ann McNeill; Greg N Connolly; Deborah Arnott; Geoffrey T Fong Journal: Tob Control Date: 2007-02 Impact factor: 7.552
Authors: James L Pirkle; John T Bernert; Samuel P Caudill; Connie S Sosnoff; Terry F Pechacek Journal: Environ Health Perspect Date: 2006-06 Impact factor: 9.031
Authors: Richard O'Connor; Clifford H Watson; Gary E Swan; Destiney S Nettles; Rebecca C Geisler; Tabitha P Hendershot Journal: Tob Control Date: 2020-01 Impact factor: 7.552
Authors: Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: David R Strong; Eric Leas; Madison Noble; Martha White; Allison Glasser; Kristie Taylor; Kathryn C Edwards; Kevin C Frissell; Wilson M Compton; Kevin P Conway; Elizabeth Lambert; Heather L Kimmel; Marushka L Silveira; Lynn C Hull; Dana van Bemmel; Megan J Schroeder; Kenneth Michael Cummings; Andrew Hyland; June Feng; Benjamin Blount; Lanqing Wang; Ray Niaura Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 5.825
Authors: Erfan Younesi; Sam Ansari; Michaela Guendel; Shiva Ahmadi; Chris Coggins; Julia Hoeng; Martin Hofmann-Apitius; Manuel C Peitsch Journal: J Biomed Semantics Date: 2014-07-10